BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10886212)

  • 21. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
    Barrett J; Guimaraes A; Cullis J; Goldman JM
    Stem Cells; 1993 Oct; 11 Suppl 3():104-8. PubMed ID: 8298471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic myeloid leukemia as an immunological target.
    Lim SH; Coleman S
    Am J Hematol; 1997 Jan; 54(1):61-7. PubMed ID: 8980262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
    Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
    Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
    Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.
    Pawelec G; Max H; Halder T; Bruserud O; Merl A; da Silva P; Kalbacher H
    Blood; 1996 Sep; 88(6):2118-24. PubMed ID: 8822931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia.
    Chen X; Regn S; Raffegerst S; Kolb HJ; Roskrow M
    Br J Haematol; 2000 Nov; 111(2):596-607. PubMed ID: 11122108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry.
    Posthuma EF; Falkenburg JH; Apperley JF; Gratwohl A; Hertenstein B; Schipper RF; Oudshoorn M; Biezen JH; Hermans J; Willemze R; Roosnek E; Niederwieser D
    Leukemia; 2000 May; 14(5):859-62. PubMed ID: 10803518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes.
    Greco G; Fruci D; Accapezzato D; Barnaba V; Nisini R; Alimena G; Montefusco E; Vigneti E; Butler R; Tanigaki N; Tosi R
    Leukemia; 1996 Apr; 10(4):693-9. PubMed ID: 8618449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
    Bosch GJ; Joosten AM; Kessler JH; Melief CJ; Leeksma OC
    Blood; 1996 Nov; 88(9):3522-7. PubMed ID: 8896419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
    Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
    Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
    Bertazzoli C; Marchesi E; Passoni L; Barni R; Ravagnani F; Lombardo C; Corneo GM; Pioltelli P; Pogliani E; Gambacorti-Passerini C
    Clin Cancer Res; 2000 May; 6(5):1931-5. PubMed ID: 10815918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
    Bilich T; Nelde A; Bichmann L; Roerden M; Salih HR; Kowalewski DJ; Schuster H; Tsou CC; Marcu A; Neidert MC; Lübke M; Rieth J; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Bauer J; Märklin M; Peper JK; Klein R; Kohlbacher O; Kanz L; Rammensee HG; Stevanović S; Walz JS
    Blood; 2019 Feb; 133(6):550-565. PubMed ID: 30530751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.
    Wagner WM; Ouyang Q; Pawelec G
    Cancer Immunol Immunother; 2003 Feb; 52(2):89-96. PubMed ID: 12594572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct.
    ten Bosch GJ; Kessler JH; Joosten AM; Bres-Vloemans AA; Geluk A; Godthelp BC; van Bergen J; Melief CJ; Leeksma OC
    Blood; 1999 Aug; 94(3):1038-45. PubMed ID: 10419896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
    Bocchia M; Wentworth PA; Southwood S; Sidney J; McGraw K; Scheinberg DA; Sette A
    Blood; 1995 May; 85(10):2680-4. PubMed ID: 7742526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation.
    Butt NM; Wang L; Abu-Eisha HM; Christmas SE; Clark RE
    Blood; 2004 Apr; 103(8):3245. PubMed ID: 15070713
    [No Abstract]   [Full Text] [Related]  

  • 37. The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.
    MacIntyre AR; Christmas SE; Clark RE
    Exp Hematol; 1996 Sep; 24(11):1307-11. PubMed ID: 8862441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The in vitro generation of Ph1+ ALL-specific HLA-A24-restricted cytotoxic T lymphocytes using a synthetic 16 mer minor bcr-abl peptide.
    Hagihara M; Tsuchiya T; Hyodo O; Ueda Y; Tazume K; Gansuvd B; Kato S; Hotta T
    Leuk Res; 2003 Mar; 27(3):253-7. PubMed ID: 12537978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
    He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
    Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.